FY2029 Earnings Estimate for VERA Issued By Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at Wedbush issued their FY2029 EPS estimates for Vera Therapeutics in a research note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico anticipates that the company will post earnings of $2.16 per share for the year. Wedbush has a “Neutral” rating and a $38.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ FY2029 earnings at $2.16 EPS.

Several other equities research analysts also recently commented on the stock. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $65.11.

Vera Therapeutics Stock Up 1.8 %

VERA opened at $29.93 on Friday. Vera Therapeutics has a fifty-two week low of $25.99 and a fifty-two week high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The firm’s fifty day moving average price is $35.75 and its two-hundred day moving average price is $40.31. The company has a market capitalization of $1.90 billion, a P/E ratio of -11.47 and a beta of 1.11.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Turn Management LLC raised its holdings in Vera Therapeutics by 53.3% during the 3rd quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock worth $14,431,000 after purchasing an additional 113,550 shares during the last quarter. SG Americas Securities LLC raised its holdings in Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock worth $857,000 after purchasing an additional 10,916 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in Vera Therapeutics by 41.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after purchasing an additional 124,197 shares during the last quarter. Barclays PLC raised its holdings in Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after purchasing an additional 41,394 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Vera Therapeutics by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company’s stock worth $15,992,000 after purchasing an additional 10,717 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 52,500 shares of company stock valued at $2,305,625 over the last ninety days. 21.70% of the stock is owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.